相关实验视频

Updated: May 2, 2026

Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments

Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments

Published on: May 31, 2017

传统中国药物的综合证据链有效性评估 (Eff-iEC):一项示范研究

Ye Luo^1,2, Xu Zhao², Ruilin Wang²

¹School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.

Acta pharmaceutica Sinica. B

|April 3, 2025

概括

一种新的方法,即基于传统中医药 (TCM) 的综合证据链有效性评估 (Eff-iEC),在评估TCM方面表现出卓越的能力. 与传统方法相比,它更好地反映了临床价值.

科学领域:

综合医学和药理学综合医学和药理学
基于证据的医学基于证据的医学.
传统中国医学 (TCM) 研究研究

背景情况:

评估传统中医药 (TCM) 的有效性是一个持续的挑战.
现有的评估系统可能无法完全捕捉TCM的细微差别.
已经提出了基于证据链的TCM综合有效性评估 (Eff-iEC) 框架.

研究的目的:

探索Eff-iEC方法在评估TCM有效性的能力.
将Eff-iEC与推,评估,开发和评估 (GRADE) 系统的分级进行比较.
评估常用的抗肝纤维化中国专利药物 (CPM) 的临床认可.

主要方法:

一项示范研究评估了六种抗肝纤维化CPM:Biejiajian药丸 (BP),大黄镇红药丸 (DZP),Biejia Ruangan化合物 (BRC),福华宇囊 (FHC),Anluo Huaxian药丸 (AHP) 和Heluo Shugan囊 (HSC).
使用Eff-iEC和GRADE系统评估了有效性证据.
通过分析这些CPM在相关医疗文件中所包含的情况来评估社区的认可.

主要成果:

BRC和FHC获得了Eff-iEC和GRADE的更高的有效性评估.
对其他CPM的评估在评估系统中各不相同.
效果-iEC分析表明,评估CPM的临床价值和社区认可与更强的相关性.

结论:

该Eff-iEC方法为TCM评估提供了一个新的认识论,更好地与临床现实和TCM推理保持一致.
与传统方法相比,Eff-iEC表现出优越的评价能力,以及评估TCM有效性的GRADE.
该方法为临床决策,新药评估和TCM健康政策制定提供了一个连贯的框架.

关键词:

抗肝纤维化抗肝纤维化中国的专利药物是中国的专利药物.临床经验临床经验临床试验中的临床试验.一个示范性研究.实验研究是实验性的研究.综合证据链综合证据链评估TCM有效性的评估

更多相关视频

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method

Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method

Published on: May 12, 2023

相关概念视频

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...